Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion

References

• Ryan TJ, Baker H. The prognosis of generalized pustular psoriasis. Br J Dermatol. 1971;85(5):407–411.
   PubMed Web of Science ®Google Scholar
• Fujita H, Terui T, Hayama K, et al., Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11): 1235–1270.
   PubMed Web of Science ®Google Scholar
• Navarini AA, Burden AD, Capon F, et al., European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11): 1792–1799.
   PubMed Web of Science ®Google Scholar
• Augey F, Renaudier P, Nicolas J-F. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16:669–673.
   PubMed Web of Science ®Google Scholar
• Löfvendahl S, Norlin JM, Schmitt-Egenolf M. Prevalence and incidence of generalised pustular psoriasis in Sweden - a population-based register study. Br J Dermatol. 2022;186(6):970–976.
   PubMed Web of Science ®Google Scholar
• Ohkawara A, Yasuda H, Kobayashi H, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996;76(1):68–71.
   PubMed Web of Science ®Google Scholar
• Choon SE, Lai NM, Mohammad NA, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676–684.
   PubMed Web of Science ®Google Scholar
• Morita A, Kotowsky N, Gao R, et al. Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: results from the Medical Data Vision claims database. J Dermatol. 2021;48(10):5–13.
   Web of Science ®Google Scholar
• Kharawala S, Golembesky AK, Bohn RL, et al. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16:239–252.
   PubMed Web of Science ®Google Scholar
• Abou-Samra T, Constantin JM, Amarger S, et al. Generalized pustular psoriasis complicated by acute respiratory distress syndrome. Br J Dermatol. 2004;150(2):353–356.
   PubMed Web of Science ®Google Scholar
• Kluger N, Bessis D, Guillot B, et al. Acute respiratory distress syndrome complicating generalized pustular psoriasis (psoriasis-associated aseptic pneumonitis). J Am Acad Dermatol. 2011;64(6):1154–1158.
   PubMed Web of Science ®Google Scholar
• Maehara Lde S, Mariano MM, Góis AF, et al. Acute respiratory distress syndrome as a complication of generalized pustular psoriasis. An Bras Dermatol. 2011;86(3):579–581.
   PubMed Web of Science ®Google Scholar
• Strober B, Kotowsky N, Medeiros R, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona Registry Dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529–541.
   PubMed Web of Science ®Google Scholar
• Sampogna F, Tabolli S, Söderfeldt B, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol. 2006;154(5):844–849.
   PubMed Web of Science ®Google Scholar
• Bachelez H. Pustular psoriasis: the dawn of a new era. Acta Derm Venereol. 2020;100(3):adv00034.
   PubMed Web of Science ®Google Scholar
• Reisner DV, Johnsson FD, Kotowsky N, et al. Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23(S1):1–7.
   PubMedGoogle Scholar
• Hanna ML, Singer D, Bender SD, et al. Characteristics of hospitalizations and emergency department visits due to generalized pustular psoriasis in the United States. Curr Med Res Opin. 2021;37(10):1697–1703.
   PubMed Web of Science ®Google Scholar
• Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(S1):21–29.
   PubMedGoogle Scholar
• Zelickson BD, Muller, SA. Generalized pustular psoriasis. A review of 63 cases. Arch Dermatol. 1991;127(9):1339–1345.
   PubMed Web of Science ®Google Scholar
• Jin H, Cho HH, Kim WJ, et al. Clinical features and course of generalized pustular psoriasis in Korea. J Dermatol. 2015;42(7):674–678.
   PubMed Web of Science ®Google Scholar
• Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266–1274.
   PubMed Web of Science ®Google Scholar
• Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–288.
   PubMed Web of Science ®Google Scholar
• Thailand FDA. Lumicef® (brodalumab) product information 2019. updated 2022 Jul 22]. cited 2022 Jul 22. Available from: https://www.fda.moph.go.th/sites/oss/Drug%20Registration/Lumicef%20Subcutaneous%20Injection%20210%20mg%20Syringe_1C%2015051-61%20(NBC)/LUMICEF%20SUBCUTANEOUS%20_SPC(8-11-19).pdf
   Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011–1017.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148–1155.
   PubMed Web of Science ®Google Scholar
• Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
   PubMed Web of Science ®Google Scholar
• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.
   PubMed Web of Science ®Google Scholar
• Burden A, Kirby B. Psoriasis and related disorders. Rook’s Textbook of Dermatology. 9 ed. New Jersey: John Wiley & Sons, Ltd; 2016.
   Google Scholar
• Martínez-Ortega JM, Nogueras P, Muñoz-Negro JE, et al. Quality of life, anxiety and depressive symptoms in patients with psoriasis: a case-control study. J Psychosom Res. 2019;124:109780.
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–65.e19.
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–1486.
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris – part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498.
   PubMed Web of Science ®Google Scholar
• National Insitute for Health and Care Excellence. Psoriasis: assessment and management. Clinical guideline. Published 2012 Oct 24, updated 2017 Sept 1. cited 2022 Jul 22. Available from: https://www.nice.org.uk/guidance/cg153
   Google Scholar
• Glickman FS. Lepra, psora, psoriasis. J Am Acad Dermatol. 1986;14(5):863–866.
   PubMed Web of Science ®Google Scholar
• Ades F, Tryfonidis K, Zardavas D. The past and future of breast cancer treatment-from the papyrus to individualised treatment approaches. Ecancermedicalscience. 2017;11:746.
   PubMed Web of Science ®Google Scholar
• Girolomoni G, de Bruin-Weller M, Aoki V, et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis. 2021;12:20406223211002979.
   Web of Science ®Google Scholar
• Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68–73.
   PubMed Web of Science ®Google Scholar
• Ohata C, Tsuruta N, Yonekura K, et al. Clinical characteristics of Japanese pustular psoriasis: a multicenter observational study. J Dermatol. 2022;49(1):142–150.
   PubMed Web of Science ®Google Scholar
• Twelves S, Mostafa A, Dand N, et al., Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3): 1021–1026.
   PubMed Web of Science ®Google Scholar
• Kromer C, Loewe E, Schaarschmidt M-L, et al. Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther. 2021;34(2):e14814.
   PubMed Web of Science ®Google Scholar
• Noe MH, Wan MT, Mostaghimi A, et al. Evaluation of a case series of patients with generalized pustular psoriasis in the United States. JAMA Dermatol. 2022;158(1):73–78.
   PubMed Web of Science ®Google Scholar
• Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89(3):432–437.
   PubMed Web of Science ®Google Scholar
• Benjegerdes KE, Hyde K, Kivelevitch D, et al. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131–144.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Takeichi T, McGrath JA, et al. Autoinflammatory keratinization diseases. J Allergy Clin Immunol. 2017;140(6):1545–1547.
   PubMed Web of Science ®Google Scholar
• Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27(10):1067–1077.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Chapter XII Diseases of the skin and subcutaneous tissue (L00-L99). World Health Organization; 2020. [cited 2022 Aug 31]. Available from: https://icd.who.int/browse10/2019/en#/XII
   Google Scholar
• Gudjonsson JE, Elder JT. Chapter 28. Psoriasis. Fitzpatrick’s Dermatology in General Medicine. 9 ed. New York: McGraw-Hill; 2019.
   Google Scholar
• Griffiths CEM, Christophers E, Barker JNWN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007;156(2):258–262.
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Gattorno M, Gul A, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis. 2018;77(11):1558–1565.
   PubMed Web of Science ®Google Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36–receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620–628.
   PubMed Web of Science ®Google Scholar
• Akiyama M. Early-onset generalized pustular psoriasis is representative of autoinflammatory keratinization diseases. J Allergy Clin Immunol. 2019;143(2):809–810.
   PubMed Web of Science ®Google Scholar
• Navarini AA, Smith CH, Barker JN, et al. Reply. J Allergy Clin Immunol. 2019;143(2):810–811.
   PubMed Web of Science ®Google Scholar
• Hospach T, Glowatzki F, Blankenburg F, et al. Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents. Pediatr Rheumatol Online J. 2019;17(1):37.
   PubMedGoogle Scholar
• Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133(11):2514–2521.
   PubMed Web of Science ®Google Scholar
• Koren J, Mburu S, Trigos D, et al. Generalised pustular psoriasis: the case for rare disease and orphan designation. Br J Dermatol. 2022; Online ahead of print. DOI:10.1111/bjd.21231.
   PubMed Web of Science ®Google Scholar
• Oji V, Luger TA. The skin in psoriasis: assessment and challenges. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S14–9.
   PubMed Web of Science ®Google Scholar
• Uppala R, Tsoi LC, Harms PW, et al. “Autoinflammatory psoriasis”-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307–317.
   PubMed Web of Science ®Google Scholar
• Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4–5):490–495.
   PubMed Web of Science ®Google Scholar
• Balan R, Grigoraş A, Popovici D, et al. The histopathological landscape of the major psoriasiform dermatoses. Arch Clin Cases. 2019;6(3):59–68.
   PubMedGoogle Scholar
• Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(S1):13–19.
   PubMedGoogle Scholar
• Fujita H, Gooderham M, Romiti R. Diagnosis of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(S1):31–38.
   PubMedGoogle Scholar
• Ly K, Beck KM, Smith MP, et al. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37–42.
   PubMed Web of Science ®Google Scholar
• Golembesky AK, Kotowsky N, Gao R, et al. PRO16 Healthcare Resource Utilization (HCRU) in patients with generalized pustular psoriasis (GPP) in Japan: a claims database study. Value Health Reg Issues. 2020;22:S98.
   Google Scholar
• Borges-Costa J, Silva R, Gonçalves L, et al. Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients. Am J Clin Dermatol. 2011;12(4):271–276.
   PubMed Web of Science ®Google Scholar
• Varman KM, Namias N, Schulman CI, et al. Acute generalized pustular psoriasis, von Zumbusch type, treated in the burn unit. A review of clinical features and new therapeutics. Burns. 2014;40(4):e35–9.
   PubMedGoogle Scholar
• Hoegler KM, John AM, Handler MZ, et al. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645–1651.
   PubMed Web of Science ®Google Scholar
• Viguier M, Allez M, Zagdanski A-M, et al. High frequency of cholestasis in generalized pustular psoriasis: evidence for neutrophilic involvement of the biliary tract. Hepatology. 2004;40(2):452–458.
   PubMed Web of Science ®Google Scholar
• Oliveira MDFSPD, Rocha BDO, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20.
   PubMed Web of Science ®Google Scholar
• Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586–592.
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Bellia G, et al. Psoriasis in pregnancy: challenges and solutions. Psoriasis (Auckl). 2015;5:83–95.
   PubMedGoogle Scholar
• Tosukhowong T, Kiratikanon S, Wonglamsam P, et al. Epidemiology and clinical features of pustular psoriasis: a 15-year retrospective cohort. J Dermatol. 2021;48(12):1931–1935.
   PubMed Web of Science ®Google Scholar
• Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives. Int J Womens Health. 2018;10:109–115.
   PubMed Web of Science ®Google Scholar
• Namazi N, Dadkhahfar S. Impetigo herpetiformis: review of pathogenesis, complication, and treatment. Dermatol Res Pract. 2018;2018:5801280.
   PubMed Web of Science ®Google Scholar
• Adachi A, Komine M, Hirano T, et al. Case of generalized pustular psoriasis exacerbated during pregnancy, successfully treated with infliximab. J Dermatol. 2016;43(12):1439–1440.
   PubMed Web of Science ®Google Scholar
• Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–2294.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741–751.
   PubMed Web of Science ®Google Scholar
• Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–539.
   PubMed Web of Science ®Google Scholar
• Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, et al. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations. J Dermatol. 2018;45(7):21–29.
   Web of Science ®Google Scholar
• Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016;152(7):825–828.
   PubMed Web of Science ®Google Scholar
• Furue K, Ito T, Tsuji G, et al. Psoriasis and the TNF/IL23/IL17 axis. Giornale Italiano di Dermatologia e Venereologia. 2019;154(4):418–424.
   PubMed Web of Science ®Google Scholar
• Garcet S, Bachelez H, Baum P, et al. Distinct patterns of gene expression in skin biopsies differentiate generalized pustular psoriasis (GPP) from psoriasis vulgaris (PV). Society for Investigative Dermatology Anual Meeting, Portland, Oregon, May 18-21; 2022
   Google Scholar
• Chang SH, Reynolds JM, Pappu BP, et al. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011;35(4):611–621.
   PubMed Web of Science ®Google Scholar
• Friedrich M, Tillack C, Wollenberg A, et al. IL-36gamma sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20(11):1891–1901.
   PubMed Web of Science ®Google Scholar
• Muromoto R, Hirao T, Tawa K, et al. IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes. Int Immunol. 2016;28(9):443–452.
   PubMed Web of Science ®Google Scholar
• Komine M, Morita A. Generalized pustular psoriasis: current management status and unmet medical needs in Japan. Expert Rev Clin Immunol. 2021;17(9):1015–1027.
   PubMed Web of Science ®Google Scholar
• Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. 2020;19(8):969–980.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907–919.
   PubMed Web of Science ®Google Scholar
• Takeichi T, Akiyama M. Generalized pustular psoriasis: clinical management and update on autoinflammatory aspects. Am J Clin Dermatol. 2020;21(2):227–236.
   PubMed Web of Science ®Google Scholar
• Gregoriou S, Kazakos C, Christofidou E, et al. Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol. 2011;21(1):104–105.
   PubMed Web of Science ®Google Scholar
• Kimura U, Kinoshita A, Haruna K, et al. Generalized pustular psoriasis-like eruptions induced after the first use of adalimumab in the treatment of psoriatic arthritis. J Dermatol. 2012;39(3):1931–1935.
   Web of Science ®Google Scholar
• Wenk KS, Claros JM, Ehrlich A. Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat. 2012;23(3):1–4.
   Web of Science ®Google Scholar
• Caca-Biljanovska N, V’lckova-Laskoska M, Laskoski D. Successful management of ustekinumab-induced pustular psoriasis without therapy discontinuation. Acta Dermatovenerol Croat. 2013;21(3):202–204.
   PubMed Web of Science ®Google Scholar
• Almutairi D, Sheasgreen C, Weizman A, et al. Generalized pustular psoriasis induced by infliximab in a patient with inflammatory bowel disease. J Cutan Med Surg. 2018;22(5):1463–1473.
   Web of Science ®Google Scholar
• Kishimoto M, Komine M, Kamiya K, et al. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47(1):33–40.
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431–2440.
   PubMed Web of Science ®Google Scholar
• Gudjonsson J, Reich A, Barker J, et al. Imsidolimab, an anti-IL-36 receptor monoclonal antibody, in the treatment of generalized pustular psoriasis: results from a phase 2 trial. European Academy of Dermatology and Venerology, Virtual; 2021. Sep-Oct 29-2.
   Google Scholar
• Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 2007;204(11):2603–2614.
   PubMed Web of Science ®Google Scholar
• Capon F. The genetic basis of psoriasis. Int J Mol Sci. 2017;18(12):2526.
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Stuart PE, Tian C, et al., Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017;8(1): 15382.
   PubMedGoogle Scholar
• Arakawa A, Siewert K, Stöhr J, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med. 2015;212(13):2203–2212.
   PubMed Web of Science ®Google Scholar
• Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42:985–990.
   PubMed Web of Science ®Google Scholar
• Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet. 2010;42(11):1000–1004.
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341–1348.
   PubMed Web of Science ®Google Scholar
• Samotij D, Szczęch J, Reich A. Generalized pustular psoriasis: divergence of innate and adaptive immunity. Int J Mol Sci. 2021;22(16):9048.
   PubMed Web of Science ®Google Scholar
• Setta-Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013;133(5):1366–1369.
   PubMed Web of Science ®Google Scholar
• Liu Z-J, Tian Y-T, Shi B-Y, et al. Association between mutation of interleukin 36 receptor antagonist and generalized pustular psoriasis: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2020;99(45):e23068.
   PubMed Web of Science ®Google Scholar
• Zhou L, Todorovic V, Kakavas S, et al. Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation. J Biol Chem. 2018;293(2):403–411.
   PubMed Web of Science ®Google Scholar
• Hussain S, Berki DM, Choon S-E, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. 2015;135(4):1067–70.e9.
   PubMed Web of Science ®Google Scholar
• Li M, Han J, Lu Z, et al. Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris. J Invest Dermatol. 2013;133(11):2637–2639.
   PubMed Web of Science ®Google Scholar
• Tauber M, Bal E, Pei XY, et al. IL36RN mutations affect protein expression and function: a basis for genotype-phenotype correlation in pustular diseases. J Invest Dermatol. 2016;136(9):1811–1819.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Twelves S, Farkas K, et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol. 2016;136(11):2251–2259.
   PubMed Web of Science ®Google Scholar
• Setta-Kaffetzi N, Simpson MA, Navarini AA, et al. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet. 2014;94(5):790–797.
   PubMed Web of Science ®Google Scholar
• Mössner R, Wilsmann-Theis D, Oji V, et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018;178(3):740–748.
   PubMed Web of Science ®Google Scholar
• Zhou J, Luo Q, Cheng Y, et al. An update on genetic basis of generalized pustular psoriasis (review). Int J Mol Med. 2021;47(6):118.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol. 2014;134(6):1755–1757.
   PubMed Web of Science ®Google Scholar
• Takeichi T, Kobayashi A, Ogawa E, et al. Autosomal dominant familial generalized pustular psoriasis caused by a CARD14 mutation. Br J Dermatol. 2017;177(4):133–135.
   Web of Science ®Google Scholar
• Mellett M, Meier B, Mohanan D, et al. CARD14 gain-of-function mutation alone is sufficient to drive IL-23/IL-17-mediated psoriasiform skin inflammation in vivo. J Invest Dermatol. 2018;138(9):2010–2023.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang S, Zheng G, et al. Gain-of-function mutation of Card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A. Immunity. 2018;49(1):66–79.e5.
   PubMed Web of Science ®Google Scholar
• Vergnano M, Mockenhaupt M, Benzian-Olsson N, et al. Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease. Am J Hum Genet. 2020;107(3):539–543.
   PubMed Web of Science ®Google Scholar
• Haskamp S, Bruns H, Hahn M, et al. Myeloperoxidase modulates inflammation in generalized pustular psoriasis and additional rare pustular skin diseases. Am J Hum Genet. 2020;107(3):527–538.
   PubMed Web of Science ®Google Scholar
• Frey S, Sticht H, Wilsmann-Theis D, et al. Rare loss-of-function mutation in SERPINA3 in generalized pustular psoriasis. J Invest Dermatol. 2020;140(7):1451–5.e13.
   PubMed Web of Science ®Google Scholar
• Johnston A, Xing X, Wolterink L, et al., IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1): 109–120.
   PubMed Web of Science ®Google Scholar
• Liang Y, Xing X, Beamer MA, et al. Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders. J Allergy Clin Immunol. 2017;139(4):1217–1227.
   PubMed Web of Science ®Google Scholar
• Baum P, Visvanathan S, Garcet S, et al. Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022;149(4):1402–1412.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32(1):227–255.
   PubMedGoogle Scholar
• Ogawa E, Sato Y, Minagawa A, et al. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45(3):264–272.
   PubMed Web of Science ®Google Scholar
• Schön MP. Adaptive and innate immunity in psoriasis and other inflammatory disorders. Front Immunol. 2019;10:1–14.
   PubMed Web of Science ®Google Scholar
• Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS One. 2019;14(8):e0220868.
   PubMed Web of Science ®Google Scholar
• Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98(1):5–13.
   PubMed Web of Science ®Google Scholar
• Furue M, Furue K, Tsuji G, et al. Interleukin-17A and keratinocytes in psoriasis. Int J Mol Sci. 2020;21(4):1275.
   PubMed Web of Science ®Google Scholar